Immune Response News and Research

RSS

Researchers identify novel strategies to develop more efficient vaccines against encapsulated bacteria

Researchers have discovered the presence of a novel subtype of innate lymphoid cells in human spleen essential for the production of antibodies. This discovery, published in the prestigious journal Nature Immunology, clears the path to the identification of novel strategies to develop more efficient vaccines against encapsulated bacteria, considered highly virulent.

24 Feb 2014

Scientists develop stem cell based method for restoring strength to damaged skeletal muscles in elderly

A study co-published in Nature Medicine this week by University of Toronto researcher Penney Gilbert has determined a stem cell based method for restoring strength to damaged skeletal muscles of the elderly.

24 Feb 2014

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

20 Feb 2014

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards are the centerpiece of the MRA research fund, which seeks to promote transformational melanoma research for swift clinical implementation.

18 Feb 2014

New research may provide insight on how dengue virus gains entry into cells

Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash. In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever.

18 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

The elusive progenitor cells that give rise to innate lymphoid cells-a recently discovered group of infection-fighting white blood cells-have been identified in fetal liver and adult bone marrow of mice, researchers from the University of Chicago report early online in the journal Nature.

14 Feb 2014

Agenus closes previously announced acquisition of 4-Antibody

Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

13 Feb 2014

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

A close cousin of the dye that makes fabric, M&M's and sports drinks blue may improve recovery from traumatic brain injuries.

12 Feb 2014

Researchers shed new light on pain associated with bacterial infections

Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them.

11 Feb 2014

Scientists identify factors that predict flu severity in patients

St. Jude Children's Research Hospital scientists have identified a signature immune response that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes. The findings also help explain why infants and toddlers are at elevated risk for flu complications. The research appears in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine.

10 Feb 2014

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Primary effusion lymphoma (PEL) is a rare B-cell neoplasm distinguished by its tendency to spread along the thin serous membranes that line body cavities without infiltrating or destroying nearby tissue.

10 Feb 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.

7 Feb 2014

Researchers design new vaccine for human-infecting respiratory syncytial virus

Vaccines are the safest, cheapest and most effective way to protect against infectious diseases. But to make a good one is still a challenge, and traditional approaches are now stretched to the limit while fatal diseases, like HIV and malaria, remain without vaccine.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

ACE protein overexpression elevates immune responses and prevents Alzheimer's-like cognitive decline

Many people with high blood pressure are familiar with ACE inhibitors, drugs that widen blood vessels by limiting activity of ACE - angiotensin-converting enzyme - a naturally occurring protein found in tissues throughout the body.

4 Feb 2014

Admedus' HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial

Admedus today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.

3 Feb 2014

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

Immune Response News and Research

Researchers identify novel strategies to develop more efficient vaccines against encapsulated bacteria

Scientists develop stem cell based method for restoring strength to damaged skeletal muscles in elderly

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

Tel Aviv University researchers win two prestigious melanoma research awards from MRA

New research may provide insight on how dengue virus gains entry into cells

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Elusive progenitor cells that give rise to ILCs identified in fetal liver and bone marrow of mice

Agenus closes previously announced acquisition of 4-Antibody

Study shows dye brilliant blue G may improve recovery from traumatic brain injuries

Researchers shed new light on pain associated with bacterial infections

Scientists identify factors that predict flu severity in patients

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Finding could lead to first effective vaccine against respiratory syncytial virus

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

Researchers design new vaccine for human-infecting respiratory syncytial virus

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

ACE protein overexpression elevates immune responses and prevents Alzheimer's-like cognitive decline

Admedus' HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial

New study reveals way to combat drug-resistant tumors

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News